Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MT 302

Next Previous
Drug Profile

MT 302

Alternative Names: MT-302

Latest Information Update: 15 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Myeloid Therapeutics
  • Developer CREATE Medicines
  • Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies; RNA
  • Mechanism of Action Immunologic cytotoxicity; Myeloid cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer; Carcinoma; Colorectal cancer; Lung cancer

Most Recent Events

  • 06 Oct 2025 Myeloid Therapeutics is now called CREATE Medicines
  • 21 Aug 2025 Amsterdam UMC Stichting plans a phase I/II SPaCE-MT trial for Oesophageal cancer and Gastric cancer (Metastatic disease) in Netherlands (EUCT2024-520213-45-00) (CTIS2024-520213-45-00)
  • 30 May 2025 Pharmacodynamics data from a phase I trial in Epithelial cancers presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO 2025).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top